Gsk Share Discussion Threads

[stewart64] 13/6/2018 12:47

May reach and hold 15.50 today.

Tbh I don't entirely understand the accounts and got in on a bit of a numbers play at 12.79.

Don't like the constant gap between basic EPS and the usually better adjusted figure. Trying to figure out the validity of the exceptionals is pretty difficult. Tbf they did adjust massively in the opposite direction two years ago. What really bothers me is when the perennial adjustment is in one direction only, up. ( like Kier).

[ny boy] 12/6/2018 19:05

Aye, steady as she goes Sir!

[warranty] 12/6/2018 18:43

Not troubled the market though and the steady climb in share price ontinues.

[alphorn] 12/6/2018 16:06

Luc Debruyne leaving looks pretty routine. Non event?

[football] 11/6/2018 09:53

30 FREE oneplus coins here but running out fast so don't miss out!!!

[garycook] 11/6/2018 09:46

11 Jun GlaxoSmithKline PLC Barclays Capital Overweight 1,538.40 1,700.00 - Reiterates

[tradermichael] 10/6/2018 15:10

The pound could be in for a wild ride this week as the U.K.’s Brexit bill goes to a vote in Parliament and that will mean volatility for GSK, I think …… ;0).

[fangorn2] 06/6/2018 17:32

As ROTW should.
Why should US taxpayers subsidise drugs for Latam, Africa,Asia or anywhere else?

[tradermichael] 06/6/2018 08:58

buywell3
5 Jun '18 - 14:15 - 17527 of 17529 (Filtered)

[abdullla] 06/6/2018 07:30

Some people think that disease only comes to others!

[jadeticl3] 05/6/2018 21:38

bw3. Please remind me why you are always writing about such things on GSK website! Why not get your articles produced in some scientific journal of some medical repute. Your offerings are wasted here, and are nothing but a nuisance.

[buywell3] 05/6/2018 14:15

News in California USA ... might it be the first human CWD case ?

Jun 04, 2018 11:04 PM PDT

''Prion disease spongiform encephalopathy is a significant underlying condition contributing to the death''

[tradermichael] 05/6/2018 07:58

“GSK collaborates on AIdriven drug design with Cloud Pharmaceuticals̶0;

By collaborating with Cloud Pharmaceuticals, GSK will be set to apply Artificial Intelligence technology to improve their drug discovery efforts.
Cloud Pharmaceutical uses its technology to accelerate the drug discovery and design process by using an Artificial Intelligence driven process to deliver tailored drug target characteristics.

The collaboration compliments GSK’s ExScientia deal last year.
CEO of cloud Pharmaceuticals, Ed Addison commented on the collaboration, “The application of our technology has proven to shorten the time from target validation to lead molecule fairly dramatically. We believe that this agreement validates the strength of the process and reinforces the value we can offer in discovering novel, high-quality drug candidates.”

[imastu pidgitaswell] 02/6/2018 08:14

Nice chart, weekly - some faffing around here and £17 to follow.

Those entries at 12.55 (Feb) and 12.87 (March) almost go as far to suggest I know what I'm doing. Almost...


free stock charts from uk.advfn.com

[mip55] 01/6/2018 13:13

GlaxoSmithKline plc (LSE/NYSE: GSK) today announces that it has completed the buyout of Novartis' 36.5% stake in its Consumer Healthcare Joint Venture for $13 billion (£9.3 billion*).

[tradermichael] 01/6/2018 13:02

Nipah Virus: Antibody to fight infection flown in from Australia
Efforts are also underway to procure the cell line which Australia used to develop the antibody. Once ICMR gets the cell line, India can start manufacturing it.

[tradermichael] 31/5/2018 11:00

British pharma major GlaxoSmithKline (LSE: GSK) has announced that its chronic obstructive pulmonary disorder (COPD) treatment Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) will be reimbursed under Australia's Pharmaceutical Benefits Scheme (PBS).

The drug is the first triple-therapy inhaler treatment to be reimbursed in Australia, and has the potential to simplify patients' treatment regimens singnificantly. Additionally, the recent IMPACT study demonstrated Trelegy Ellipta's superiority to two of GSK's older COPD treatments, Anoro (umeclidinium and vilanterol) and Breo (fluticasone furoate and vilanterol).

Heather Allan, chief executive of the Lung Foundation Australia, was pleased to see more options become available for COPD patients:

"Not only does COPD have a serious impact on our public health system, but its impact on the quality of life of those affected is particularly marked," she said. "Medications are a critical element of the treatment of COPD aimed at managing symptoms and reducing the risk of exacerbation."

[tradermichael] 31/5/2018 10:56

AstraZeneca’s hopes for expanding severe asthma drug Fasenra into chronic obstructive pulmonary disease are officially lost.
Wednesday, the British drugmaker said the therapy had flopped a phase 3 trial—its second of two—testing the drug in patients with moderate to very severe COPD.

Fasenra missed the primary endpoint of the study, dubbed Terranova, failing to significantly cut down on episodes when symptoms suddenly worsened.

AstraZeneca made a similar announcement earlier this month after Fasenra fell short in a separate phase 3 study, Galathea, though at the time it said it would wait for the Terranova results to roll in before making any decisions.

Now, though, there’s not much left to do besides “analyze the complete data sets … to further understand these results,” R&D chief Sean Bohen said in a statement, adding that, “These results are disappointing.”;

Fasenra’s dashed COPD prospects mark a big setback for AstraZeneca, which was looking to give respiratory rival GlaxoSmithKline a run for its money. Though GSK had a two-year head start with Fasenra’s in-class rival, Nucala, AZ execs hoped Fasenra’s less-frequent dosing could help it poach market share. It is dosed every eight weeks after the first three doses, a less frequent schedule than Nucala.

Unlike Fasenra, though, Nucala has already shown it can improve exacerbation rates. In a phase 3 study, the drug beat out placebo at paring down the frequency of moderate and severe episodes in patients with higher blood eosinophil counts, a biomarker targeted by this class of drugs. Now, Glaxo is waiting for a decision from the FDA—and if it gets a green light, it’ll give the company a major edge over AstraZeneca.

GSK is getting ahead outside of asthma and COPD, too. Back in December, it picked up an FDA go-ahead for Nucala to treat eosinophilic granulomatosis with polyangiitis (EGPA), a chronic rare disease caused by inflammation in the walls of blood vessels.

[tim 3] 30/5/2018 21:53

Momentum and trend to continue for much longer than people think .As you can see from the chart GSK is now comfortably out performing the FTSE .Would not surprise me if we eventually head back to £17.

[ny boy] 30/5/2018 19:31

1485p is the support now, bounced off nicely, heading to try and break 1540p resistance in the short term

[tradermichael] 30/5/2018 15:17

About 20p (or so) to go and we can resume the path we were on 6 months ago before Emma's little speech …. ;0)

[ny boy] 29/5/2018 09:46

I guess a safe haven during market corrections, ev3n though it’s off a bit but less than other stocks. I doubt much lower than 1473p, certainly that level needs to hold.

[tradermichael] 29/5/2018 08:22

GlaxoSmithKline and Innoviva said Tuesday they submitted a regulatory application to the Japanese Ministry of Health, Labour and Welfare for their single inhaler triple therapy for the treatment of patients with chronic obstructive pulmonary disease or COPD.

The new drug application for once-daily fluticasone under the proposed brand name of Trelegy Ellipta was primarily based on data from the Phase III IMPACT study which included 378 patients from Japan, GSK said.

'COPD is a debilitating lung disease affecting over five million people in Japan. Many patients require combination treatment with different types of medicines to reduce both symptoms and exacerbations but there is currently no triple therapy available in Japan delivered in a single inhaler,' said Dave Allen, Head, Respiratory Therapy Area R&D.

'If approved, once-daily FF/UMEC/VI delivered in the Ellipta would be an important innovation in the management of COPD in Japan alongside our current range of treatments.'

[dr biotech] 29/5/2018 07:48

Thing I found odd is as an external contractor is I have to surrender my phone at Worthing but am allowed to keep it at the other sites. The GSK paaport is quite quite handy though so I don’t have to sit through the H&S induction every visit. The people at Ware I know better, always been deal with.

Decent announcement this morning, though I doubt itll move the share price japanesnhave their own pharmacopoeia so it takes extra work...